DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injuryhourshearttraumaticto determine
  Phrases that lowered it: clinical trialdrugsfreethe effectcognitive
• Sponsor's past termination rate: 14.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 43 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 12.0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor's past trials: 117 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 75.9% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 10 (lowers risk) · Design
• Maximum age: 64 (lowers risk) · Who can join
• Drug's FAERS reports before start: 19771 (raises risk) · Drug's FDA history
• Minimum age: 16 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Early Propranolol After Traumatic Brain Injury: Phase II NCT01202110 · started 2010 · scored riskier than 90% of active trials terminated
• Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury NCT02012582 · started 2009 · scored riskier than 52% of active trials completed
• Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury NCT01093261 · started 2010 · scored riskier than 96% of active trials completed
• Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury. NCT01762475 · started 2013 · scored riskier than 36% of active trials completed
• Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury NCT00704379 · started 2008 · scored riskier than 67% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.